Search results

Filter

Filetype

Your search for "*" yielded 562452 hits

Nya rön om genetiken vid äggstockscancer

Ett stort internationellt forskarsamarbete har funnit 12 nya gener eller loci (platser på en kromosom) som ökar risken för äggstockscancer. Analysen har omfattat över 25 000 patienter, nära 41 000 kontroller och 31 000 kvinnor med de två viktigaste riskgenerna för bröstcancer. En artikel om forskningsfynden, som forskare vid Lunds universitet bidragit till, har nyligen publicerats i Nature Genetic

https://www.lu.se/artikel/nya-ron-om-genetiken-vid-aggstockscancer - 2026-07-27

Rymdens gåtor lockar toppforskare till Lund

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. Den 4 april kommer världsledande astronomiforskare till Lunds universitet för att diskutera de stora frågorna inom astrofysiken. Det handlar exempelvis om mörk materia, galaxers evolution och upptäckterna av nya planeter utanför vårt solsystem. Symposiet är det första av Knut och Alice Wallenbergs Stiftelses jubileu

https://www.lu.se/artikel/rymdens-gator-lockar-toppforskare-till-lund - 2026-07-27

Ny kurs om och för cancerpatienter och närstående

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. En ny – och förmodligen världsunik– kurs tar plats i höstens programutbud från Lunds universitet: en fristående distanskurs om att vara cancerpatient eller närstående till en cancersjuk person. Kursen har utformats av tre fakulteter; LTH, Socialhögskolan och medicinska fakulteten och vänder sig till patienter, anhör

https://www.lu.se/artikel/ny-kurs-om-och-cancerpatienter-och-narstaende - 2026-07-27

Tens of thousands sign up for AI-related MOOC

Lund University’s fastest growing online course can have up to a thousand new participants every week. ‘AI, business and the future of work’ is a success story – but behind it lies many hours of hard work. “In total, we have probably spent 8,000 hours preparing and producing the course,” says Anamaria Dutceac Segesten, currently senior lecturer in European Studies and deputy dean of the Joint Facu

https://www.ai.lu.se/article/tens-thousands-sign-ai-related-mooc - 2026-07-27

AI is better than humans at analysing long-term ECG recordings

In patients with symptoms such as irregular heartbeats, dizziness, or fainting, or in individuals that physicians suspect may have atrial fibrillation, many days of ECGs may be required for diagnosis – “long-term ECG recordings”. These recordings must then undergo a time-consuming and human resource-intensive review to identify heart rhythm abnormalities. In a large international study, researcher

https://www.ai.lu.se/article/ai-better-humans-analysing-long-term-ecg-recordings - 2026-07-27

AI-supported breast cancer screening – new results suggest even higher accuracy

New research results now published from Lund University’s MASAI trial are even better than the initial findings from last year: AI-supported breast screening detected 29 per cent more cases of cancer compared with traditional screening. More invasive cancers were also clearly detected at an early stage using AI. Now the final part of the research study will focus on breast cancer missed by screeni

https://www.ai.lu.se/article/ai-supported-breast-cancer-screening-new-results-suggest-even-higher-accuracy - 2026-07-27

The Conversation: How AI ‘sees’ the world – what happened when we trained a deep learning model to identify poverty

To most effectively deliver aid to alleviate poverty, you have to know where the people most in need are. In many countries, this is often done with household surveys. But these are usually infrequent and cover limited locations.Recent advances in artificial intelligence (AI) have created a step change in how to measure poverty and other human development indicators. Our team has used a type of AI

https://www.ai.lu.se/article/conversation-how-ai-sees-world-what-happened-when-we-trained-deep-learning-model-identify-poverty - 2026-07-27

Johan Axhamn represented Lund at the Swedish Riksdag’s seminar on AI

Every year, the Swedish Riksdag organises a research day. This year the theme was “artificial intelligence”. The aim is to give Members of Parliament the opportunity to gain new knowledge and to highlight the value of science for politics, democracy, and parliamentary decision-making. This year, Johan Axhamn, senior lecturer in Business Law here at LUSEM, was the sole representative from Lund Univ

https://www.ai.lu.se/article/johan-axhamn-represented-lund-swedish-riksdags-seminar-ai - 2026-07-27

Is OA linked to cancer?

In a new Swedish study by Lund University on comorbidities in osteoarthritis, researchers studied if people with osteoarthritis are at an increased risk for cancer compared to people without osteoarthritis. The study focused on the four most common cancer types, lung, colon, breast, and prostate cancer. Researchers found no differences in the risk of being diagnosed with colon cancer if you had os

https://www.arthritisportal.lu.se/article/oa-linked-cancer - 2026-07-27

Your genes play a part in the development of OA and perceived joint pain

Previous studies from Iceland have shown how osteoarthritis is often inherited and can be traced back several generations. A gene (genetic predisposition) is a segment of DNA containing hereditary information and is inherited from our biological parents. A new international study published in the high-ranking scientific journal Cell has discovered that a large number of genes are associated with o

https://www.arthritisportal.lu.se/article/your-genes-play-part-development-oa-and-perceived-joint-pain - 2026-07-27

Devil's Claw - the herbal medicine with a continued uncertain effect on OA pain

Devil's Claw (Harpagophytum procumbens) is a plant in the sesame family native South Africa that has long been used as a herbal medicine to treat a number of different diseases. The plant is believed to be able to reduce joint pain and joint stiffness as it is said to have analgesic and anti-inflammatory properties. However, the actual properties of devil's claw are yet not fully understood. There

https://www.arthritisportal.lu.se/article/devils-claw-herbal-medicine-continued-uncertain-effect-oa-pain - 2026-07-27

The global burden of osteoarthritis

Osteoarthritis has been described as the 15th most common cause of so-called “years lived with disability” (YLDs) in the world, which is a measure used to shed light on the burden of various diseases on society. According to the researchers, the economic costs caused by the disease correspond to about 1-2.5% of the gross domestic product (GDP) in most countries. A new article from a group of Ameri

https://www.arthritisportal.lu.se/article/global-burden-osteoarthritis - 2026-07-27

Common comorbidities in osteoarthritis

In a new Swedish study by Lund University, researchers looked at how common it is with comorbidities in osteoarthritis of the knee and/or hip. The study was published in the American journal Arthritis Care & Research. The study analyzed data collected from the province of Scania's population between the years 1998 and 2017. Newly diagnosed osteoarthritis patients were at a slightly higher risk of

https://www.arthritisportal.lu.se/article/common-comorbidities-osteoarthritis - 2026-07-27

The effect of PRP on ankle OA: No better than placebo

Earlier in October, we reported on a research study that showed that platelet-rich plasma (PRP) injections for treating osteoarthritis of the knee did not have a better effect on OA symptoms than placebo. Last week, results from a new study on PRP were published. The researchers concluded that PRP injections had no effect on ankle OA compared to placebo. The Dutch study included 100 ankle OA patie

https://www.arthritisportal.lu.se/article/effect-prp-ankle-oa-no-better-placebo - 2026-07-27

Not approved in the EU: Another setback for the drug tanezumab

The painkiller tanezumab was not approved by the European Medicine's Agency. At the beginning of 2021, news came that tanezumab, a new pain medication, would be launched in the US and Europe.  However, in March, tanezumab suffered a setback in the United States when the US Food and Drug Administration rejected the drug for osteoarthritis pain. There was continued uncertainty about the launch of th

https://www.arthritisportal.lu.se/article/not-approved-eu-another-setback-drug-tanezumab - 2026-07-27

The many risks of the painkiller tramadol

Tramadol is an increasingly common drug prescribed for pain. Tramadol is a synthetic opioid (manufactured in a lab) that differs somewhat in its chemical structure compared to the natural opioid codeine. Other opioids include morphine and heroin. All opioids have analgesic properties and are extremely addictive. In a new study based on primary care data from Spain, the risks of a number of side ef

https://www.arthritisportal.lu.se/article/many-risks-painkiller-tramadol - 2026-07-27

The benefits and side effects of common pain meds for osteoarthritis of the knee and hip

In a new meta-analysis (a compilation of results from a number of different research studies), the benefits and side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), paracetamol, and opioids have been studied. The research study included data from 181 publications describing 192 clinical trials involving a total of over 100,000 patients. The researchers found that the NSAID etoricoxib (6

https://www.arthritisportal.lu.se/article/benefits-and-side-effects-common-pain-meds-osteoarthritis-knee-and-hip - 2026-07-27

How common is knee osteoarthritis?

A Chinese research group has compiled data from 88 different scientific studies on the prevalence of knee osteoarthritis. The studies were from all around the world and together included more than 10 million people. The researchers estimated that for individuals aged 40 years and older, the global prevalence of knee osteoarthritis is around 23%. This means that almost every fourth person over the

https://www.arthritisportal.lu.se/article/how-common-knee-osteoarthritis - 2026-07-27

PRP injections no more effective than placebo

PRP treatment (platelet-rich plasma) is a relatively new experimental treatment that is often marketed to be effective for patients with osteoarthritis. However, there is a lack of high-quality research claiming the effectiveness of the treatment. Researchers from Brazil have recently published results from a small clinical trial (including 61 patients) evaluating three different treatments. The p

https://www.arthritisportal.lu.se/article/prp-injections-no-more-effective-placebo - 2026-07-27

Osteoarthritis roundtable: Best from the ACR conference 2021

Doctors Jack Cush, Martin Englund, Gillian Hawker, Tihuna Neogi, and Kent Kwoh discuss the best OA research from the 2021 ACR (American College of Rheumatology) conference, including a new study indicating that the diabetes medicine metformin lowers the risk of developing osteoarthritis. Dr. Jack Cush is a professor of internal medicine at The University of Texas Southwestern Medical School, in th

https://www.arthritisportal.lu.se/article/osteoarthritis-roundtable-best-acr-conference-2021 - 2026-07-27